Remove Download Remove Drug Development Remove Drugs
article thumbnail

New Report Reveals Trends, Opportunities in Drug Development

PPD

As the clinical trial landscape evolves, drug developers are faced with novel challenges and changes in study recruitment, trial size and structure, and more. The adoption of new innovations, strategies and technologies offers opportunities to address persistent challenges and develop suitable approaches for the future.

article thumbnail

Increasing the probability of technical success in drug development using AI and patient heterogeneity

Predictive Oncology

Most drug failures occur in Phase II and Phase III clinical trials when drugs move from immortalized cell lines and animal testing to human patients. By combining these two assets, this offering represents an opportunity to de-risk drug discovery and accelerate pipeline development.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Essential Roadmap to Drug Development for Bioanalytical Success

Fierce BioTech

The Essential Roadmap to Drug Development for Bioanalytical Success Discover the 3 pillars of successful PK testing and conquer bioanalytical challenges with this whitepaper’s insights. Download now.

article thumbnail

Survey Uncovers Global Challenges and Opportunities in Drug Development

PPD

The PPD clinical research business of Thermo Fisher Scientific has surveyed more than 150 drug developers around the globe to gather annual data on trends in pharmaceutical research and development. Applying artificial intelligence (AI) to drug development (e.g., mRNA, drug discovery platforms) ranked as the No.

article thumbnail

Heterogeneous and curated biobank of live-cell tumor samples retains highly reproducible drug response data for drug and biomarker discovery

Predictive Oncology

White paper validates highly reproducible drug response data. The ability to introduce patient heterogeneity in the discovery and development stages increases the Probability of Technical Success (PTS) and reduces the risk inherent in all aspects of the drug development pipeline.

Drugs 52
article thumbnail

Heterogeneous and curated biobank of live-cell tumor samples retains highly reproducible drug response data for drug and biomarker discovery

Predictive Oncology

White paper validates highly reproducible drug response data. The ability to introduce patient heterogeneity in the discovery and development stages increases the Probability of Technical Success (PTS) and reduces the risk inherent in all aspects of the drug development pipeline.

Drugs 52
article thumbnail

How next-generation phage display libraries are accelerating antibody developability

Fierce BioTech

How next-generation phage display libraries are accelerating antibody developability Download now to learn how a next-generation phage library is overcoming the limitations of traditional antibody discovery platforms, enhancing the discovery of highly specific and effective antibody-based therapies.